> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Novo Nordisk Wins Priority Review Voucher
- URL: https://www.fdaweb.com/novo-nordisk-wins-priority-review-voucher/
- Published: 2025-01-14T12:00:00.000Z
- Updated: 2026-09-14T14:50:53.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5158479

*Federal Register* notice: FDA is announcing that it has issued Novo Nordisk a priority review voucher because its rare pediatric disease product, Alhemo (concizumab-mtci), met the agency’s issuance criteria. The product was approved 12/20/2024 as a once-a-day treatment to prevent or curb the frequency of bleeding episodes in patients ages 12 and older who have hemophilia A or B with inhibitors. To view the notice, click [here](https://public-inspection.federalregister.gov/2025-00750.pdf?ref=fdaweb.com).